Return to homepagePandemic Pact

Exploring the Role of RIP140 in Regulating the Acute Inflammatory Response in COVID-19 Patients

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • start year

    -99

  • Known Financial Commitments (USD)

    $0

  • Funder

    University of Minnesota

  • Principal Investigator

    MD. Pat Arndt

  • Research Location

    United States of America

  • Lead Research Institution

    Medical School, University of Minnesota

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen morphology, shedding & natural history

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

While targeting individual mediators regulating this storm may be beneficial in the treatment of COVID-19, an understanding of the mechanisms regulating the upstream pathways controlling this acute inflammatory response will allow for the identification of novel targets in the design of pharmacologic agents to treat COVID-19 infection. In this study, Pat Arndt, MD, associate professor of medicine, will examine the expression and localization of the transcriptional co-regulatory factor receptor interacting protein (RIP) 140, which regulates the pro-inflammatory response, in neutrophils and lymphocytes. "Pharmacological blockade of RIP140 by small molecule inhibitors may decrease the COVID-19 induced cytokine storm and accentuate an anti-inflammatory response that would enhance healing, particularly lung repair," said Arndt.